Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New upgrade:   Journal your trades with more detail

Read How
Market News Market Pulse Stocks News ETF News Crypto News

vTv Therapeutics Inc.

Contributing Author

Recent Articles by vTv Therapeutics Inc.

Aug-19
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
Aug-06
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update VTVT GlobeNewswire
Jul-28
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
Jul-02
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
Jun-02
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
May-13
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update VTVT VTVT +21.36% GlobeNewswire
May-08
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
May-07
vTv Therapeutics to Participate in Upcoming May Investor Conferences VTVT GlobeNewswire
Apr-07
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
Mar-16
vTv Therapeutics to Participate in the 38th Annual ROTH Conference VTVT +14.57% GlobeNewswire
Mar-10
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update VTVT GlobeNewswire
Feb-13
vTv Therapeutics to Participate in Upcoming Investor Conferences VTVT -7.18% GlobeNewswire
Feb-02
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 VTVT +8.19% GlobeNewswire
Dec-18
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health VTVT GlobeNewswire
Nov-06
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update VTVT +5.07% GlobeNewswire
Oct-09
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board VTVT GlobeNewswire
Sep-15
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting VTVT GlobeNewswire
Sep-03
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences VTVT GlobeNewswire
Sep-03
vTv Therapeutics to Participate in Upcoming September Investor Conferences VTVT GlobeNewswire
Sep-02
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund VTVT +13.30% GlobeNewswire
Aug-12
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update VTVT -6.35% GlobeNewswire
Aug-11
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin VTVT +10.52% GlobeNewswire
Aug-07
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes VTVT GlobeNewswire
Jun-11
vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series VTVT GlobeNewswire
May-19
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin VTVT GlobeNewswire
May-15
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update VTVT +5.16% VTVT -6.16% GlobeNewswire
May-15
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes VTVT +5.16% VTVT -6.16% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)